GlassScriptPhysician profile
Jonathan Alexander Miles
NPI 1295296036
$5,432.21
in general payments reported to CMS, 2019-2025
22 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 88% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $261 · 2023: $898 · 2024: $2,016 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.66 |
| Education | $265.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.10 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $825.16 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $541.73 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $540.98 | 2023-2025 | |
| Galderma Laboratories, L.P. | $539.41 | 2023-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $410.66 | 2024-2025 | |
| Lilly USA, LLC | $263.17 | 2023-2025 | Taltz, Zepbound, Ebglyss |
| Ucb, INC. | $224.47 | 2023-2025 | Bimzelx |
| Pfizer INC. | $196.66 | 2022-2025 | |
| Amgen INC. | $188.09 | 2023-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $148.59 | 2023 | Tremfya |
| Janssen Biotech, INC. | $147.81 | 2024-2025 | Tremfya |
| Incyte Corporation | $132.17 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $117.25 | 2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.87 | 2024 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $39.15 | 2025 | Zoryve |
| Biofrontera INC. | $38.22 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.81 | 2024-2025 | Cabtreo, Jublia |
| Botanix Sb INC | $32.97 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $22.34 | 2023 | Ycanth |
| Blueprint Medicines Corporation | $13.77 | 2023 | |
| Organon LLC | $11.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.